Daily Probiotic Boosts Antidepressant Effects in Older Adults Study Finds
A 12-week clinical trial found older adults taking probiotics with antidepressants had greater reductions in depression and anxiety than placebo.
Summary
A small clinical trial published in the Journal of the American Geriatrics Society found that older adults with moderate depression who took a daily probiotic alongside their antidepressant medication experienced greater improvements in depression and anxiety symptoms compared to those on placebo. The 12-week study of 58 adults aged 60 and older in India also examined BDNF levels and gut microbiome composition. While both groups improved, the probiotic group showed modestly better outcomes. Researchers believe the gut-brain connection — the biological dialogue between gut microbes and brain function — may partly explain the benefit. The findings are preliminary but suggest probiotics could be a safe, low-risk add-on to standard depression treatment in older adults.
Detailed Summary
Depression in older adults is a serious and often undertreated condition, and finding safe adjunct therapies is a growing priority in geriatric medicine. This small but meaningful clinical trial adds to the emerging evidence that the gut microbiome may play a role in mental health — and that probiotics could complement existing treatments.
The study enrolled 58 Indian adults aged 60 and older, all diagnosed with moderate depression and already receiving standard antidepressant therapy. Participants were randomly assigned to take either a daily probiotic supplement or a placebo for 12 weeks, with an additional 12-week follow-up period. Both groups showed meaningful symptom improvement, but the probiotic group experienced somewhat greater reductions in both depression and anxiety scores on established clinical rating scales.
Researchers also measured BDNF — brain-derived neurotrophic factor — a protein critical to nerve cell growth and survival that is frequently implicated in mood disorders. Additionally, they conducted fecal microbiota profiling to assess changes in gut bacteria composition. These biological markers helped contextualize the symptom improvements and support the plausibility of a gut-brain mechanism driving the results.
Interestingly, the probiotic group did not show statistically meaningful improvements in overall quality of life compared to placebo — suggesting that while mood symptoms improved, broader wellbeing measures may require longer intervention or larger effect sizes to detect changes.
The primary caveat here is scale: 58 participants is a pilot study, and results should be considered hypothesis-generating rather than definitive. The study was conducted in a single country, limiting generalizability. Larger, more diverse trials are needed to confirm which probiotic strains are most effective, which patients respond best, and how long benefits persist. Still, given the safety profile of probiotics and the burden of late-life depression, these findings are worth watching closely.
Key Findings
- Older adults taking daily probiotics with antidepressants showed greater depression and anxiety symptom reduction than placebo group.
- The 12-week probiotic intervention was well-tolerated as an add-on to standard antidepressant treatment in adults 60 and older.
- BDNF levels and gut microbiome composition were tracked, suggesting a biological gut-brain mechanism behind the mood benefits.
- No significant improvement in overall quality of life was detected in the probiotic group versus placebo.
- Findings are preliminary from a 58-person pilot trial; larger diverse studies are needed to confirm results.
Methodology
This is a research summary based on a peer-reviewed pilot RCT published in the Journal of the American Geriatrics Society, a credible peer-reviewed journal. The study is a randomized placebo-controlled trial with 58 participants, which limits statistical power. Evidence quality is preliminary but scientifically grounded with biological marker analysis.
Study Limitations
The sample size of 58 participants is small, limiting generalizability and statistical confidence in the findings. The study was conducted solely in India, so results may not apply across different populations, diets, or microbiome compositions. The specific probiotic strain, dose, and long-term durability of effects are not detailed in the summary and should be verified in the primary publication.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.